



Imunexus Company Profile

Overview

Imunexus Ltd is a new public unlisted Australian company based in Melbourne that develops bi- and trispecific antibody-based drugs and promises exceptional growth potential in the fields of oncology and immune-oncology. Imunexus has derived its core technology and drug product pipeline from work carried out by its founding members.

Imunexus is applying its patented technology to overcome key limitations of existing antibody drugs by adding additional therapeutic function(s) to these antibodies via a quick and simple conversion into bi- or trispecifics. As a bi- or trispecific, these retrofitted antibodies are now better equipped at killing cancer cells by enhancing the way they engage the body's own immune system and/or they can now target multiple sites on the one target cell or protein to increase specificity or induce synergistic induction. In effect, Imunexus quickly and easily creates more potent versions of existing drugs.

Imunexus differentiates from other bispecific companies via the modular nature and retrofitting capability of its technology that allows an unprecedented level of flexibility for generating multispecifics from existing antibodies (or other proteins). This gives Imunexus a clear path forward for creating multispecific antibodies and provides rapid, cost effective and de-risked drug development. Currently Imunexus has 7 multispecific products in its pipeline with many more pending.

Speaker Profile

Dr George Kopsidas, Executive Director, Chief Scientific Officer, Imunexus Ltd



Prior to Imunexus, George was a practised molecular biologist and biotechnologist with over 17 years' experience in protein and antibody drug engineering, 5 years' experience in the field of molecular ageing and mitochondrial diseases where he held a position on the editorial board for the Bio-Gerontology Journal, and well over 10 years' experience elucidating the mechanisms of DNA repair. He held academic positions with RMIT and La Trobe Universities and held a Research Fellowship at the National Institutes of Health USA (NIH). He has had senior roles in the commercial sector as the Senior Scientist with the Centre for Molecular Biology and Medicine, the Director of Protein Technologies at Evogenix Ltd, and the Vice President of Protein Technologies at both Arana Therapeutics and Cephalon.

continued...



He has multiple international publications, holds patents with Evogenix Ltd, Arana Therapeutics and Cephalon, holds joint patents with GlaxoSmithKline, TeVa Pharmaceuticals and Vegenics and has presented 45 papers at national and international conferences. Recently he had founded and managed a successful biotechnology consulting company, Meliccept Pty Ltd, which consulted around therapeutics and biotechnology, developed strategic business plans, budgets and resource development and performed due diligence on accessible IP around platforms for novel therapeutic approaches. Most recently, he founded Imunexus Ltd where he took on the roles of Executive Director and Chief Scientific Officer.

For more information, please visit: imunexus.com